Drugs for Machado-Joseph Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 35)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Mexiletine |
Approved, Investigational |
Phase 4 |
|
31828-71-4 |
4178 |
Synonyms:
(+-)-1-(2,6-dimethylphenoxy)propan-2-amine
(+-)-1-(2,6-Dimethylphenoxy)propan-2-amine
(±)-1-(2,6-dimethylphenoxy)propan-2-amine
(2Rs)-1-(2,6-Dimethylphenoxy)-2-aminopropane
(2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane
1-(2',6'-dimethylphenoxy)-2-aminopropane
1-(2',6'-Dimethylphenoxy)-2-aminopropane
1-(2,6-dimethylphenoxy)-2-propanamine
1-(2,6-Dimethylphenoxy)-2-propanamine
1-(2,6-dimethylphenoxy)propan-2-amine
1-methyl-2-(2,6-xylyloxy)ethanamine
1-Methyl-2-(2,6-xylyloxy)ethanamine
1-Methyl-2-(2,6-xylyloxy)ethylamine
2-(2-aminopropoxy)-1,3-dimethylbenzene
2-(2-Aminopropoxy)-1,3-DiMethyl-Benzene Hydrochloride
31828-71-4
5370-01-4 (hydrochloride)
AB00053683
AC1L1HL7
AC1Q2BC5
AC1Q2BC6
Boehringer ingelheim brand OF mexiletine hydrochloride
BPBio1_000026
BRD-A64092382-003-04-3
BRN 2092205
BSPBio_000022
BSPBio_002254
C07220
CHEBI:115958
CHEBI:6916
CHEMBL558
CID4178
D08215
DB00379
DivK1c_000834
EINECS 250-825-7
I01-6374
IDI1_000834
KBio1_000834
KBio2_002082
KBio2_004650
KBio2_007218
|
KBio3_001474
KBioGR_001270
KBioSS_002082
KO1173
KO-1173
KOE-1173
Lopac0_000784
LS-68257
Mexiletene
Mexiletina
Mexiletina [INN-Spanish]
Mexiletine
Mexilétine
Mexiletine (INN)
Mexiletine [INN:BAN]
Mexiletine HCL
Mexiletine hydrochloride
Mexiletinum
Mexiletinum [INN-Latin]
Mexilitine
Mexitil
Mexitil PL
Mexityl
MolPort-001-790-944
NCGC00015659-04
NCGC00162253-01
NCGC00162253-02
NINDS_000834
novo Mexiletine
novo-Mexiletine
Novopharm brand OF mexiletine hydrochloride
Prestwick0_000241
Prestwick1_000241
Prestwick2_000241
Prestwick3_000241
SBB070242
SPBio_002241
Spectrum_001602
Spectrum3_000727
Spectrum4_000795
Spectrum5_001279
UNII-1U511HHV4Z
|
|
2 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
3 |
|
Sodium Channel Blockers |
|
Phase 4 |
|
|
|
4 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
5 |
|
TA 0910 |
|
Phase 4 |
|
|
|
6 |
|
Lithium carbonate |
Approved |
Phase 2, Phase 3 |
|
554-13-2 |
|
Synonyms:
Carbonic acid, dilithium salt
Dilithium carbonate
Lithii carbonas
|
Lithium carbonate
Lithonate
|
|
7 |
|
Riluzole |
Approved, Investigational |
Phase 3 |
|
1744-22-5 |
5070 |
Synonyms:
1744-22-5
2 amino 6 Trifluoromethoxybenzothiazole
2-amino-6-(trifluoromethoxy)-1,3-benzothiazole
2-amino-6-(trifluoromethoxy)benzo[d]thiazole
2-Amino-6-(trifluoromethoxy)benzothiazole
2-Amino-6-(trifluoromethoxy)-benzothiazole
2-amino-6-(trifluoromethoxyl)benzothiazole
2-Amino-6-trifluoro- methoxybenzothiazole
2-amino-6-trifluoromethoxybenzothiazole
2-amino-6-Trifluoromethoxybenzothiazole
6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
6-(trifluoromethoxy)benzo[d]thiazol-2-amine
6-Trifluoromethoxy-benzothiazol-2-ylamine
6-trifluoromethoxybenzothiazole-2-yl-amine
AC1L1JJL
AC1Q530H
AC-730
AKOS000265071
ALBB-006046
Amino-2 trifluoromethoxy-6 benzothiazole
Amino-2 trifluoromethoxy-6 benzothiazole [French]
Aventis behring brand OF riluzole
Aventis brand OF riluzole
BB_SC-4839
BF-37
BIDD:GT0055
Bio1_000416
Bio1_000905
Bio1_001394
Biomol-NT_000245
BPBio1_000037
BPBio1_000837
BRD-K21283037-001-02-5
BRD-K21283037-003-03-9
BSPBio_000033
C07937
C8H5F3N2OS
CHEMBL744
CID5070
D00775
DB00740
EU-0101064
FT-0082997
HMS1773G08
HMS2089O19
HMS2094G07
I01-2084
Impax brand OF riluzole
Lopac0_001064
|
Lopac-R-116
LS-40688
MLS000069369
MolPort-000-151-262
NCGC00015882-01
NCGC00015882-02
NCGC00015882-03
NCGC00015882-07
NCGC00015882-11
NCGC00023141-02
NCGC00023141-04
NCGC00023141-05
NCGC00023141-06
PK-26124
PK-26124, RP-54274, Rilutek, Riluzole
Prestwick0_000167
Prestwick-03A08
Prestwick1_000167
Prestwick2_000167
Prestwick3_000167
R-116
R116_SIGMA
Rhone poulenc rorer brand OF riluzole
Rhone-poulenc rorer brand OF riluzole
Rilutek
Rilutek (TN)
Riluzol
Riluzol [INN-Spanish]
riluzole
Riluzole
Riluzole (JAN/USAN/INN)
Riluzole [USAN:INN]
Riluzole aventis brand
Riluzole HCl
Riluzole impax brand
Riluzolum
Riluzolum [INN-Latin]
RP 54274
RP-54274
S1614_Selleck
SMR000058231
SPBio_000599
SPBio_001954
Spectrum2_000550
STK503686
Tocris-0768
UNII-7LJ087RS6F
ZERO/001785
ZINC00006481
|
|
8 |
|
Glutamic acid |
Approved, Nutraceutical |
Phase 3 |
|
56-86-0 |
33032 |
Synonyms:
(2S)-2-Aminopentanedioate
(2S)-2-Aminopentanedioic acid
(S)-(+)-Glutamate
(S)-(+)-Glutamic acid
(S)-2-Aminopentanedioate
(S)-2-Aminopentanedioic acid
(S)-Glutamate
(S)-Glutamic acid
09581_FLUKA
10549-13-0
138-15-8 (unspecified hydrochloride)
138-16-9
16690-92-9 (di-hydrochloride salt)
19238-49-4 (unspecified calcium salt)
19473-49-5 (mono-potassium salt)
1-amino-Propane-1,3-dicarboxylate
1-Aminopropane-1,3-dicarboxylate
1-amino-Propane-1,3-dicarboxylic acid
1-Aminopropane-1,3-dicarboxylic acid
1ftj
1ii5
1xff
24595-14-0 (unspecified potassium salt)
24938-00-9
25513-46-6
26717-13-5
27322E29-9696-49C1-B541-86BEF72DE2F3
2-Aminoglutarate
2-Aminoglutaric acid
2-Aminopentanedioate
2-aminopentanedioic acid
2-Aminopentanedioic acid
49449_FLUKA
49449_SIGMA
55695-80-2 (mono-lithium salt)
56-86-0
6899-05-4
7558-63-6 (mono-ammonium salt)
84960-48-5
a-Aminoglutarate
a-Aminoglutaric acid
AB1002631
AC-11294
AC1L1OVN
AC1Q28OF
AC1Q4U8B
AC1Q4U8C
Acide glutamique
Acide glutamique [INN-French]
acido Glutamico
Acido glutamico
ácido glutámico
Acido glutamico [INN-Spanish]
Acidum glutamicum
Acidum glutamicum [INN-Latin]
Acidum glutaminicum
Aciglut
a-Glutamate
a-Glutamic acid
AI3-18472
alpha-Aminoglutarate
alpha-aminoglutaric acid
alpha-Aminoglutaric acid
alpha-Aminoglutaric acid (VAN)
alpha-Glutamate
alpha-Glutamic acid
alpha-L-Glutamic acid polymer
Aluminum L glutamate
Aluminum L-glutamate
AmbotzHAA1087
Aminoglutarate
Aminoglutaric acid
Biomol-NT_000170
BPBio1_001132
C00025
CCRIS 7314
CHEBI:16015
CHEMBL575060
CID33032
D Glutamate
D00007
DB00142
DB02517
D-Glutamate
D-Glutamiensuur
E
E 620
EINECS 200-293-7
EPA Pesticide Chemical Code 374350
FEMA No. 3285
|
FT-0085107
G0059
G1251_SIGMA
G5667_SIGMA
G8415_SIGMA
Glt
glu
Glu
Glusate
glut
Glut
glutacid
Glutacid
glutamate
Glutamate
Glutamate, potassium
Glutamic acid
GLUTAMIC ACID
Glutamic acid (H-3)
Glutamic Acid (L-glutamic acid)
Glutamic acid (VAN)
Glutamic Acid [USAN:INN]
Glutamic acid polymer
Glutamic acid, (D)-isomer
Glutamic acid, L- (7CI,8CI)
Glutamic acid, L-, peptides
Glutamicol
Glutamidex
Glutaminate
glutaminic acid
Glutaminic acid
Glutaminic acid (VAN)
Glutaminol
Glutaton
Gulutamine
Gulutamine (USP)
H-Glu-OH
HSCI1_000269
L Glutamate
L Glutamic acid
L-(+)-Glutamate
L-(+)-glutamic acid
L-(+)-Glutamic acid
L-2-Aminoglutaric acid
L-a-Aminoglutarate
L-a-Aminoglutaric acid
L-alpha-Aminoglutarate
L-alpha-Aminoglutaric acid
L-glu
L-Glu
L-glutamate
L-Glutamate
L-Glutamate, aluminum
L-glutamic acid
L-Glutamic acid
L-Glutamic acid (9CI)
L-Glutamic acid (JAN)
L-Glutamic acid hydrochloride
L-Glutamic acid, homopolymer
L-Glutamic acid, homopolymer (9CI)
L-Glutaminate
L-Glutaminic acid
L-Glutaminsaeure
Lopac0_000529
LS-2330
LS-71885
MolPort-001-770-254
NCGC00024502-01
NCGC00024502-02
NCGC00024502-03
NCGC00024502-04
nchembio.186-comp9
nchembio.198-comp6
nchembio.2007.55-comp22
nchembio.266-comp23
nchembio.586-comp22
nchembio816-comp2
NSC 143503
PDSP1_000128
PDSP1_001539
PDSP2_000127
PDSP2_001523
Poly(alpha-L-glutamic acid)
POLYGLUTAMIC ACID
Poly-L-glutamate
Potassium glutamate
Sodium Glutamate (L-glutamic Acid)
Tocris-0218
UNII-3KX376GY7L
W328502_ALDRICH
|
|
9 |
|
Antidepressive Agents |
|
Phase 2, Phase 3 |
|
|
|
10 |
|
Psychotropic Drugs |
|
Phase 2, Phase 3 |
|
|
|
11 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
12 |
|
Excitatory Amino Acid Antagonists |
|
Phase 3 |
|
|
|
13 |
|
Neuroprotective Agents |
|
Phase 3 |
|
|
|
14 |
|
Anticonvulsants |
|
Phase 3 |
|
|
|
15 |
|
Protective Agents |
|
Phase 3 |
|
|
|
16 |
|
Varenicline |
Approved, Investigational |
Phase 2 |
|
249296-44-4 |
5310966 |
Synonyms:
249296-44-4
6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino(2,3-H)Benzazepine
7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino(2,3-H)(3)Benzazepine
7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine
7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline
AC1L55H0
AC1Q4W6H
AKOS005145561
AR-1H2911
Champix
Chantix
CHEBI:430452
CHEMBL1396
CID170361
|
CP 526555
CP-526,555
D08669
HSDB 7591
I14-1963
LS-187375
Tartrate, varenicline
UNII-W6HS99O8ZO
Vareniclina
varenicline
Varenicline
Varenicline (INN)
Varenicline tartrate
Vareniclinum
|
|
17 |
|
Menthol |
Approved |
Phase 2 |
|
2216-51-5 |
16666 |
Synonyms:
(−
(−)-(1R,3R,4S)-menthol
(-)-(1R,3R,4S)-Menthol
(-)-menthol
(−)-menthol
()-Menthol
(-)-Menthol
(-)-Menthyl alcohol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(-)-trans-P-Menthan-cis-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(1a,2b,5a)-5-Methyl-2(1-methylethyl)cyclohexanol
(1alpha,2beta,5alpha)-5-methyl-2(1-methylethyl)cyclohexanol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1R-(1-a,2-b,5-a))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1R-(1-α,2-β,5-α))-5-methyl-2-(1-methylethyl)cyclohexanol
(1R)-(-)-Menthol
(1r,2s,5r)-(-)-menthol
(1R,2S,5R)-(-)-Menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(−)-menthol
(1R,3R,4S)-(-)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1α,2β,5α)-5-methyl-2(1-methylethyl)cyclohexanol
(L)-MENTHOL
(R)-(-)-Menthol
)-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
1-Menthol
20747-49-3
2216-51-5
2-Isopropyl-5-methylcyclohexanol
3-p-Menthol
491-02-1
4-Isopropyl-1-methylcyclohexan-3-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
5-Methyl-2-(1-methylethyl)cyclohexanol
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
5-Methyl-2-propan-2-ylcyclohexan-1-ol
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
Caswell No. 540
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
D-(-)-Menthol
d,l-Menthol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
d-Menthol
d-Neomenthol
D-p-Menthan-3-ol
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
|
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
Headache crystals
Hexahydrothymol
HMS1922G13
HMS2092L14
HMS502I22
HSDB 5662
HSDB 593
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
Kerasal
l-(-)-Menthol
L-(-)-Menthol
Levomenthol
Lévomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
l-Menthol
L-menthol
L-Menthol
l-Menthol (JP15)
l-Menthol (natural)
l-Menthol (TN)
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
M0321
M0545
M2772_SIAL
Menthacamphor
MENTHOL
--MENTHOL
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-isomer
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
Mentol
MLS002207256
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
nchembio862-comp1
NCI-C50000
Neoisomenthol
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Peppermint camphor
p-Menthan-3-ol
P-Menthan-3-ol
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
RACEMIC MENTHOL U.S.P.
rac-Menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
Spectrum_000305
SPECTRUM1503134
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
STK802468
Tra-kill tracheal mite killer
U.S.p. menthol
U.S.P. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
|
|
18 |
|
Nicotinic Agonists |
|
Phase 2 |
|
|
|
19 |
|
Cholinergic Agents |
|
Phase 2 |
|
|
|
20 |
|
Antibodies |
|
Phase 2 |
|
|
|
21 |
|
Rho(D) Immune Globulin |
|
Phase 2 |
|
|
|
22 |
|
gamma-Globulins |
|
Phase 2 |
|
|
|
23 |
|
Immunoglobulins, Intravenous |
|
Phase 2 |
|
|
|
24 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
25 |
|
Calcium, Dietary |
|
Phase 2 |
|
|
|
26 |
|
Calcium |
Nutraceutical |
Phase 2 |
|
7440-70-2 |
271 |
Synonyms:
Blood coagulation factor XIII
Ca
Ca(2+)
Ca2+
Calcio
Calcium
Calcium element
CALCIUM ion
Calcium, doubly charged positive ion
Calcium, elemental
Coagulation factor XIII
Elemental calcium
Factor XIII
|
Factor XIII a chain
Factor XIII a-chain
Factor XIII transamidase
Factor XIII, coagulation
Fibrin stabilizing factor
Fibrinase
Kalzium
Laki lorand factor
Laki-lorand factor
Stabilizing factor, fibrin
Transamidase, factor XIII
XIII, coagulation factor
|
|
27 |
|
Pharmaceutical Solutions |
|
Phase 1 |
|
|
|
28 |
|
Immunologic Factors |
|
Phase 1 |
|
|
|
29 |
|
4-Aminopyridine |
Approved |
|
|
504-24-5 |
1727 |
Synonyms:
.gamma.-Aminopyridine
[J.Pharmacol.Exp.Ther. 275:864 (1995)]
275875_ALDRICH
36687_FLUKA
36687_RIEDEL
4 Aminopyridine
4 Aminopyridine Sustained Release
4 AP
4-aminopyridine
4-Aminopyridine
4-Aminopyridine 10
4-Aminopyridine Sustained Release
4-AP
4-Pyridinamine
4-Pyridylamine
504-24-5
5-22-09-00106 (Beilstein Handbook Reference)
A 0152
A0414
A78403_ALDRICH
AB1004971
AC1L1C3R
AC1Q52BM
AC-907/25014071
AI3-52547
AKOS000119896
Amaya
Amino-4 pyridine
Amino-4-Pyridine
Ampydin
Ampyra
Avitrol
Avitrol 200
BB_SC-6974
Bio1_000353
Bio1_000842
Bio1_001331
Bio2_000282
Bio2_000762
BRN 0105782
BSPBio_001562
C13728
C5H6N2
Caswell No. 038
CHEBI:34385
CHEMBL284348
CID1727
Compound 1861
D015761
D04127
Dalfampridine
DivK1c_000572
EINECS 207-987-9
EL-970
EPA Pesticide Chemical Code 069201
EU-0100032
Fampridina
Fampridine
Fampridine (USAN/INN)
Fampridine [USAN:INN]
Fampridine SR
Fampridine-PR
Fampridine-SR
Fampridinum
FT-0083754
gamma-Aminopyridine
HC150041
HMS1361O04
HMS1791O04
HMS1921H15
HMS1989O04
HMS2092F05
HMS501M14
HSDB 6037
IDI1_000572
IDI1_034032
|
InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7
KBio1_000572
KBio2_000282
KBio2_000635
KBio2_002850
KBio2_003203
KBio2_005418
KBio2_005771
KBio3_000563
KBio3_000564
KBio3_001888
KBioGR_000282
KBioGR_001505
KBioSS_000282
KBioSS_000635
Lopac0_000032
Lopac-A-0152
LS-130202
Mi-W-3
MLS000069400
MolPort-000-146-022
NCGC00015009-01
NCGC00015009-03
NCGC00015009-12
NCGC00024890-01
NCGC00024890-02
NCGC00024890-03
NCGC00024890-04
NCGC00024890-05
NCGC00024890-06
NCGC00024890-07
NCGC00024890-08
NCGC00024890-09
NCGC00024890-10
nchem.892-comp4
Neurelan
Neurelan (TN)
NINDS_000572
NSC 15041
NSC15041
p-Aminopyridine
p-Aminopyridine [UN2671] [Poison]
p-Aminopyridine [UN2671] [Poison]
Philips 1861
Phillips 1861
Pimadin (free base)
Prc 1237
Pymadin
Pymadine
pyridin-4-amine
pyridin-4-ylamine
PYRIDINE,4-AMINO
RCRA waste no. P008
SDCCGMLS-0066228.P001
SMR000058211
SPBio_001486
Spectrum_000155
SPECTRUM1501130
Spectrum2_001413
Spectrum3_000914
Spectrum4_001013
Spectrum5_001501
STK298717
Sustained Release, 4-Aminopyridine
TL8003344
Tocris-0940
UNII-BH3B64OKL9
UPCMLD-DP125
UPCMLD-DP125:001
VMI 103
VMI 10-3
VMI103
VMI-103
VMI-10-3
WLN: T6NJ DZ
γ-Aminopyridine
|
|
30 |
|
tannic acid |
Approved |
|
|
1401-55-4 |
|
Synonyms:
ácido tánico
Gallotannic acid
|
|
|
31 |
|
Benzocaine |
Approved, Investigational |
|
|
94-09-7, 1994-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
|
Ethyl aminobenzoic acid
Ethyl PABA
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl P-aminobenzoate
Ethyl P-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny P-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
P-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
P-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
P-Carbethoxyaniline
p-Ethoxycarboxylic aniline
P-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
32 |
|
Dopamine |
Approved |
|
|
51-61-6, 62-31-7 |
681 |
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
33 |
|
Potassium Channel Blockers |
|
|
|
|
|
34 |
|
Dopamine agonists |
|
|
|
|
|
35 |
|
Omega 3 Fatty Acid |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 62)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Mexiletine for the Treatment of Muscle Cramps in ALS |
Completed |
NCT01811355 |
Phase 4 |
Mexiletine;Placebo |
2 |
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IV Clinical Trial to Evaluate and Compare the Safety and Efficacy of C-Trelin OD Tab 5mg(Taltirelin Hydrate) in Patients With Ataxia Induced by Spinocerebellar Degeneration |
Recruiting |
NCT04107740 |
Phase 4 |
C-Trelin OD Tab(5mg Taltirelin Hydrate);Placebo |
3 |
Randomized Clinical Trial to Assess the Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3 |
Completed |
NCT01096082 |
Phase 2, Phase 3 |
Lithium Carbonate;Placebo |
4 |
Efficacy of Riluzole in Hereditary Cerebellar Ataxia: a Randomized Double-blind Placebo-controlled Trial. |
Completed |
NCT01104649 |
Phase 2, Phase 3 |
riluzole;Placebo comparator |
5 |
A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia. |
Recruiting |
NCT03701399 |
Phase 3 |
troriluzole;Placebos |
6 |
Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 |
Recruiting |
NCT03347344 |
Phase 3 |
Riluzole;Placebo |
7 |
An Open Pilot Trial of BHV-4157 in Adult Subjects With Cerebellar Ataxia |
Active, not recruiting |
NCT03408080 |
Phase 3 |
BHV-4157 |
8 |
A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia |
Active, not recruiting |
NCT02960893 |
Phase 2, Phase 3 |
Troriluzole;Placebo Comparator |
9 |
A Clinical Research on the Safety/Efficacy of Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Spinocerebellar Ataxia |
Unknown status |
NCT03378414 |
Phase 2 |
|
10 |
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study to Evaluate the Safety and Efficacy of Stemchymal® Infusion for the Treatment of Polyglutamine Spinocerebellar Ataxia |
Unknown status |
NCT02540655 |
Phase 2 |
|
11 |
Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia |
Unknown status |
NCT01360164 |
Phase 1, Phase 2 |
|
12 |
The Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Transplantation in Hereditary Cerebellar Ataxia Patients |
Unknown status |
NCT01489267 |
Phase 2 |
|
13 |
The Influence of Deep Repetitive Transcranial Magnetic Stimulation (TMS) on Cerebellar Signs in Patients With Spinocerebellar Ataxia Type 3 (SCA3 - Machado Joseph Disease) |
Completed |
NCT02039206 |
Phase 2 |
|
14 |
A Pilot, Randomized, Double-blind, Placebo-controlled Phase I Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3 |
Completed |
NCT00992771 |
Phase 2 |
varenicline;placebo |
15 |
A Single-Center, Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta® in Patients With Machado-Joseph Disease |
Completed |
NCT02147886 |
Phase 2 |
Cabaletta for IV infusion once weekly during 24 weeks;Cabaletta for IV infusion once weekly during 24 weeks |
16 |
Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia |
Completed |
NCT01350440 |
Phase 2 |
|
17 |
Randomized, Placebo-controlled Trial to Test Safety, Tolerability and Efficacy of Lithium Carbonate in Spinocerebellar Ataxia 2 |
Completed |
NCT00998634 |
Phase 2 |
LITHIUM CARBONATE |
18 |
Phase 2 Study of Riluzole Effects on Patients With Chronic Cerebellar Ataxia |
Completed |
NCT00202397 |
Phase 2 |
Riluzole |
19 |
Effect of Nilotinib in Cerebellar Ataxia Patients |
Active, not recruiting |
NCT03932669 |
Phase 2 |
Nilotinib |
20 |
Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of CAD-1883 in Adults With Spinocerebellar Ataxia (Synchrony-1) |
Suspended |
NCT04301284 |
Phase 2 |
CAD-1883;Placebos |
21 |
Phenylbutyrate in SCA3: a Double-blind, Placebo-controlled Study to Determine Safety and Efficacy of Sodium Phenylbutyrate in Patients With SCA3 |
Withdrawn |
NCT01096095 |
Phase 2 |
Placebo;Sodium Phenylbutyrate |
22 |
An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias |
Unknown status |
NCT02287064 |
Phase 1 |
Intravenous Immune Globulin (IVIG) |
23 |
Pilot Study of Tolerability of Lithium Therapy in Patients With Spinocerebellar Ataxia Type I (SCA1) |
Completed |
NCT00683943 |
Phase 1 |
Lithium Carbonate |
24 |
Machado-Joseph Disease in Israel: Clinical Phenotype and Genotype of a Jew Yemenite Subpopulation |
Unknown status |
NCT02175290 |
|
|
25 |
Prospective Study of Individuals at Risk for Spinocerebellar Ataxia Type 1, Type 2, Type 3, Type 6 and Type 7 (SCA1, SCA2, SCA3, SCA6, SCA7) |
Unknown status |
NCT01037777 |
|
|
26 |
Slowing Down Disease Progression in Premanifest SCA: a Piloting Interventional Exergame Trial |
Unknown status |
NCT02867969 |
|
|
27 |
Non Invasive Prenatal Diagnosis on Isolated Circulating Fetal Trophoblastic Cells (CFTC) for Triplet Repeat Diseases |
Unknown status |
NCT03087526 |
|
|
28 |
Clinical Effects of Oral Trehalose In Patients With Spinocerebellar Ataxia 3: A Pilot Study |
Completed |
NCT04426149 |
|
|
29 |
Weight in Lower Limbs Improves Gait Ataxia Of in Machado-Joseph Disease Patients: A Randomized Crossover Trial |
Completed |
NCT02906046 |
|
|
30 |
Dysmetria in Motor Function in SCA: Mechanisms and Rehabilitation |
Completed |
NCT02488031 |
|
|
31 |
Therapeutic Effect of Dalfampridine on Gait Incoordination in Spinocerebellar Ataxias- A Randomized, Double-blinded, Placebo-controlled, Crossover Clinical Trial |
Completed |
NCT01811706 |
|
Dalfampridine;Placebo |
32 |
Rehabilitative Trial With Cerebello-Spinal tDCS for the Treatment of Neurodegenerative Ataxia |
Completed |
NCT03120013 |
|
|
33 |
Integrative Medicine and Tai-chi in Clinical Status of Spinocerebellar Ataxia |
Completed |
NCT03687190 |
|
conventional medicine |
34 |
Utility Of Home Based Gait Monitoring, Performance Scores And Functional Visual Assessment In Spinocerebellar Ataxias (SCA) |
Completed |
NCT00654251 |
|
|
35 |
Characterization of the Parkinsonism and Other Non-ataxia Spectrum and Striatal Dopaminergic Degeneration in Spinocerebellar Ataxia Type 6 |
Completed |
NCT01934998 |
|
|
36 |
Pathogenic Mechanism of Spinocerebellar Ataxia Type 10 (SCA10) |
Completed |
NCT00004306 |
|
|
37 |
Neuromuscular Electrical Stimulation on Median Nerve Facilitates Low Motor Cortex Excitability in Human With Spinocerebellar Ataxia |
Completed |
NCT02103075 |
|
|
38 |
Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND) |
Completed |
NCT02179333 |
|
|
39 |
Coordination Training With Complete Body Video Games in Children and Adults With Degenerative Ataxias |
Completed |
NCT02874911 |
|
|
40 |
The Effect of Whole Body Vibration Training on Neuromuscular Property in Individuals With Ataxia |
Completed |
NCT01983631 |
|
|
41 |
Effects of Aerobic Exercise on Degenerative Cerebellar Disease |
Completed |
NCT03745248 |
|
|
42 |
Transcranial Magnetic Stimulation (TMS) in Spino-Cerebellar Ataxia |
Completed |
NCT01975909 |
|
|
43 |
Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias |
Completed |
NCT01488461 |
|
|
44 |
The Investigation of the Pre-movement Facilitation of Agonist-antagonist Muscles and the Effect of the Feedforward Rehabilitation in Individuals With Hypermetria |
Completed |
NCT01983670 |
|
|
45 |
Identification of Biomarkers in Patients With Autosomal Dominant Cerebellar Ataxia |
Completed |
NCT01470729 |
|
|
46 |
Translating Molecular Pathology Into a Therapeutic Strategy in SCA38, a Newly Identified Form of Spinocerebellar Ataxia |
Completed |
NCT03109626 |
|
|
47 |
A Randomised Controlled Trial on the Clinical Efficacy of Oral Trehalose in Patients With Spinocerebellar Ataxia 3: Clinical & FMRI Correlation |
Recruiting |
NCT04399265 |
Early Phase 1 |
|
48 |
Clinical Trial Readiness for SCA1 and SCA3 |
Recruiting |
NCT03487367 |
|
|
49 |
APDM Instrumented Data Exchange for Ataxia (IDEA) Study |
Recruiting |
NCT04268147 |
|
|
50 |
Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) to Study Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias (SCA) |
Recruiting |
NCT01060371 |
|
|
|